BridgeBio Pharma EPS - Earnings per Share 2018-2024 | BBIO
BridgeBio Pharma eps - earnings per share from 2018 to 2024. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| BridgeBio Pharma Annual EPS |
| 2023 |
$-3.95 |
| 2022 |
$-3.26 |
| 2021 |
$-3.90 |
| 2020 |
$-3.80 |
| 2019 |
$-2.48 |
| 2018 |
$-2.12 |
| 2017 |
$-1.00 |
| BridgeBio Pharma Quarterly EPS |
| 2024-09-30 |
$-0.86 |
| 2024-06-30 |
$-0.39 |
| 2024-03-31 |
$-0.20 |
| 2023-12-31 |
$-0.97 |
| 2023-09-30 |
$-1.08 |
| 2023-06-30 |
$-0.98 |
| 2023-03-31 |
$-0.92 |
| 2022-12-31 |
$-0.91 |
| 2022-09-30 |
$-0.93 |
| 2022-06-30 |
$-0.07 |
| 2022-03-31 |
$-1.35 |
| 2021-12-31 |
$-1.00 |
| 2021-09-30 |
$-1.06 |
| 2021-06-30 |
$-0.66 |
| 2021-03-31 |
$-1.18 |
| 2020-12-31 |
$-1.01 |
| 2020-09-30 |
$-0.98 |
| 2020-06-30 |
$-1.03 |
| 2020-03-31 |
$-0.78 |
| 2019-12-31 |
$-0.60 |
| 2019-09-30 |
$-0.51 |
| 2019-06-30 |
$-0.71 |
| 2019-03-31 |
$-0.66 |
| 2018-12-31 |
$0.00 |
| 2018-09-30 |
$-0.52 |
| 2017-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.426B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
